Last reviewed · How we verify

Rifaximin 550 MG

Bonderup, Ole K., M.D. · FDA-approved active Small molecule Quality 2/100

Rifaximin 550 MG is a Small molecule drug developed by Bonderup, Ole K., M.D.. It is currently FDA-approved. Also known as: Xifaxan, Rifaxa 550MG, Nimixa 550 MG, Xifaxa 550MG.

At a glance

Generic nameRifaximin 550 MG
Also known asXifaxan, Rifaxa 550MG, Nimixa 550 MG, Xifaxa 550MG, Zerifax 550MG
SponsorBonderup, Ole K., M.D.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rifaximin 550 MG

What is Rifaximin 550 MG?

Rifaximin 550 MG is a Small molecule drug developed by Bonderup, Ole K., M.D..

Who makes Rifaximin 550 MG?

Rifaximin 550 MG is developed and marketed by Bonderup, Ole K., M.D. (see full Bonderup, Ole K., M.D. pipeline at /company/bonderup-ole-k-m-d).

Is Rifaximin 550 MG also known as anything else?

Rifaximin 550 MG is also known as Xifaxan, Rifaxa 550MG, Nimixa 550 MG, Xifaxa 550MG, Zerifax 550MG.

What development phase is Rifaximin 550 MG in?

Rifaximin 550 MG is FDA-approved (marketed).

Related